Novel TDP1 Inhibitors: Disubstituted Thiazolidine-2,4-Diones Containing Monoterpene Moieties
作者:Dmitry I. Ivankin、Tatyana E. Kornienko、Marina A. Mikhailova、Nadezhda S. Dyrkheeva、Alexandra L. Zakharenko、Chigozie Achara、Jóhannes Reynisson、Victor M. Golyshev、Olga A. Luzina、Konstantin P. Volcho、Nariman F. Salakhutdinov、Olga I. Lavrik
DOI:10.3390/ijms24043834
日期:——
target for antitumor therapy; the use of TDP1 inhibitors with a topoisomerase 1 poison such as topotecan is a potential combination therapy. In this work, a novel series of 3,5-disubstituted thiazolidine-2,4-diones was synthesized and tested against TDP1. The screening revealed some active compounds with IC50 values less than 5 μM. Interestingly, compounds 20d and 21d were the most active, with IC50 values
酪氨酰-DNA-磷酸二酯酶 1 (TDP1) 是一个很有前途的抗肿瘤治疗靶点;将 TDP1 抑制剂与拓扑异构酶 1 毒药(如拓扑替康)结合使用是一种潜在的联合疗法。在这项工作中,合成了一系列新的 3,5-二取代噻唑烷-2,4-二酮并针对 TDP1 进行了测试。筛选揭示了一些 IC50 值小于 5 μM 的活性化合物。有趣的是,化合物 20d 和 21d 的活性最强,IC50 值在亚微摩尔浓度范围内。在 1-100 μM 的浓度范围内,没有一种化合物显示出对 HCT-116(结肠癌)和 MRC-5(人肺成纤维细胞)细胞系的细胞毒性。最后,这类化合物不会使癌细胞对拓扑替康的细胞毒性作用敏感。